ARCHITECT (R) urine-neutrophil gelatinase-associated lipocalin (u-NGAL) assay as new prognostic marker for clear cell Renal Cell Carcinoma (ccRCC) (preliminary results) - Université de Picardie Jules Verne Accéder directement au contenu
Article Dans Une Revue International Urology and Nephrology Année : 2021

ARCHITECT (R) urine-neutrophil gelatinase-associated lipocalin (u-NGAL) assay as new prognostic marker for clear cell Renal Cell Carcinoma (ccRCC) (preliminary results)

Résumé

Introduction Biomarkers for the diagnosis and monitoring treatment response of kidney cancer are urgently needed. Neutrophil gelatinase-associated lipocalin (NGAL) is a relevant urinary biomarker for the diagnosis of a wide variety of acute and chronic kidney diseases. Its potential utility as a prognostic marker of kidney cancer is largely unknown and, therefore, was the subject of this investigation. Materials and methods A retrospective study was done on 50 kidney tumor patients (urine samples prospectively collected before nephrectomy between 2004 and 2012, stored at Biobank Resource Center). The specificity, sensitivity and the predictive value of NGAL were determined for progression-free and disease-specific survival after nephrectomy in renal cell carcinoma (particularly, the clear cell renal cell carcinoma (ccRCC)). Urinary NGAL concentration (u-NGAL) was determined by CMIA technique (ARCHITECT (R) urine NGAL essay/ABBOTT(R)). Results Out of the 50 kidney tumor patients, 40 had clear cell carcinoma with a median u-NGAL excretion of 1.4 (IQR: 5.76) ng/mg urinary creatinine (Ucr). u-NGAL was correlated to tumor stage (p = 0.005), and Fuhrman grade (p = 0.0002). Multivariate Cox regression analysis showed a significant association between u-NGAL excretion and clear cell renal cell carcinoma progression free survival and disease specific survival (p = 0.002;p = 0.0001). Conclusions Urinary NGAL was significantly associated with the stage and the grade of kidney cancer. u-NGAL excretion could be considered as a potential biomarker to identify ccRCC patients with the more pejorative outcomes.
Fichier non déposé

Dates et versions

hal-03573033 , version 1 (14-02-2022)

Identifiants

Citer

Hajer Ben Khadhra, Francoise Rose-Robert, Yves Edouard Herpe, Henri Sevestre, Gabriel Choukroun, et al.. ARCHITECT (R) urine-neutrophil gelatinase-associated lipocalin (u-NGAL) assay as new prognostic marker for clear cell Renal Cell Carcinoma (ccRCC) (preliminary results). International Urology and Nephrology, 2021, 53 (1), pp.59-67. ⟨10.1007/s11255-020-02604-w⟩. ⟨hal-03573033⟩
15 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More